Organophosphorus pesticides are the most widely used pesticides in modern agricultural systems to ensure good harvests. Isocarbophos (ICP), with a potent acetylcholinesterase inhibitory effect is widely utilized to control a variety of leaf-eating and soil insects. However, the characteristics of the bioactivation and detoxification of ICP in humans remain unclear. In this study, the oxidative metabolism, esterase hydrolysis, and chiral inversion of ICP in human liver microsomes (HLMs) were investigated with the aid of a stereoselective LC/MS/MS method. The depletion of ICP in HLMs was faster in the absence of carboxylesterase inhibitor (BNPP) than in the presence of NADPH and BNPP, with t 1/2 of 5.2 and 90 min, respectively. Carboxylesterase was found to be responsible for the hydrolysis of ICP, the major metabolic pathway. CYP3A4, CYP1A2, CYP2D6, CYP2C9, and CYP2C19 were all involved in the secondary metabolism pathway of desulfuration of ICP. Flavin-containing monooxygenase (FMO) did not contribute to the clearance of ICP. The hydrolysis and desulfuration of (±)ICP, (+)ICP, and (−)ICP in HLMs follow Michaelis-Menten kinetics. Individual enantiomers of ICP and its oxidative desulfuration metabolite isocarbophos oxon (ICPO) were found to be inhibitors of acetylcholinesterases at different extents. For example, (±)ICPO is more potent than ICP (IC 50 0.031M vs. 192M), whereas (+)ICPO is more potent than (−)ICPO (IC 50 0.017M vs. 1.55M). Given the finding of rapid hydrolysis of ICP and low abundance of oxidative metabolites presence in human liver, the current study highlights that human liver has a greater capacity for detoxification of ICP.
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Organophosphorus pesticides (OP) are the most widely used pesticides in modern agricultural systems to ensure good harvests (Barr et al., 2004) . Isocarbophos (O-2-isopropoxycarbonylphenyl O-methyl phosphoramidothioate, ICP), a highly effective organophosphorus insecticide and acaricide, was originally synthesized in 1967 by the Bayer Company (Wang et al., 2005) . ICP, a potent acetylcholinesterase inhibitor, is widely utilized to control a variety of leaf-eating and soil insects such as aphids, spider mites, borers, and leaf rollers on rice, cotton, fruit, and other crops. ICP was introduced into China in 1981, and the current annual production for agricultural usage is about 5000 ton (Jia et al., 2006) . ICP is a moderate toxic compound, and displays a great difference in toxicity among its enantiomers (Lin et al., 2008) , with the median lethal concentration (LC 50 ) toward Daphnia magna range 13.9-353 mg/l after 48 h of static exposure. Although ICP was banned from being used on vegetable growth in China, accidental exposure to occupational personnel during manufacture and formulation processes and off label domestic usage often result in human poisoning, e.g., serious incidents and suicidal attempts were frequently reported (Yamashita et al., 1997) . Species difference in pesticide metabolism also brings in another challenge in understanding of ICP disposition in humans (Nishi et al., 2006; Ross et al., 2006) . For example, Godin et al. (2006) reported that deltamethrin was eliminated primarily via the NADPH-dependent oxidative metabolism in rat liver microsomes, whereas it was eliminated almost entirely through a NADPH-independent hydrolytic pathway in human liver microsomes. Thus, in vitro investigations with human derived enzymes are of high values in understanding the pesticides disposition and toxicity in humans.
It is well-accepted that the acute toxic effects of organophosphorothioate pesticides are primarily due to the inhibition of acetylcholinesterase (AChE) in cholinergic synapses of neurons in the central nervous system and skeletal muscle (Kwong, 2002) . The cytochrome P450 (CYP) mediated metabolites, bioactivated intermediates, are usually the active chemical entities for the AChE inhibition (Abel et al., 2004) . For example, the oxidative desulfuration of chlorpyrifos (CP) generates a highly electrophilic intermediate, CP-oxon (CPO), which exhibits a three magnitudes higher affinity toward the active site
Enantiomers of isocarbophos (ICP) and its oxidative desulfuration metabolite (ICP-oxon, ICPO).
of serine-dependent ester hydrolase compared with the parent compound (Amitai et al., 1998) . Different CYPs are often found to metabolize different OPs (Buratti et al., 2003) . In addition, the hydrolysis of oxons to inactive metabolites by liver A-esterases (paraoxonase 1, PON1), B-esterases (carboxylesterase), or butyrylcholinesterase (BChE) represents the main detoxication pathways of ICP (Pond et al., 1995) . In some cases, such as malathion, these enzymes are also able to hydrolyze both parent and its oxon metabolites to their inactive metabolites (Kutz et al., 1992) . Therefore, a better understanding of the ICP metabolism in humans is crucial for understanding ICP toxicokinetics and individual tolerability. On the other hand, the characterization of bioactivation and detoxification of ICP has not yet been extensively investigated and reported.
Survey of 70 commercial available organophosphorothioate pesticides found that about 30 of them have chiral centers (Garrison, 2006) . Many chiral OPs such as methamidophos, chlora-midophos, fosthiazate, trichloronate, leptophos, and fenamiphos display enantiomer-specific acute toxicities Liu et al., 2006; Wang et al., 2004; Zhou et al., 2007) . The bioactivation of ICP generates active metabolite (ICP-oxon, ICPO) via oxidative desulfuration. Both ICP and ICPO consist of pairs of enantiomers with asymmetric centers at the phosphorus atom (Fig. 1) . Lin et al. (2008) have proved that there is about 50-fold difference in inhibition (LC 50 ) toward D. magna between these enantiomers, the (+)enantiomer and (−)enantiomer of ICP. In HepG2 cells, enantiomers of ICP showed a significant enantioselective cytotoxicity, i.e., (−)ICP was about twice more toxic than (+)ICP (Liu et al., 2010) . However, the enantioselective ICP metabolism in liver and their inhibitory effects on acetylcholinesterase remain unclear.
The aims of the present study were to investigate the following aspects in HLMs and recombinant CYPs: (1) to identify the human P450 enzymes and their relative contributions to the bioactivation of ICP to ICPO; (2) to evaluate the detoxification rate of ICP by esterase hydrolysis; (3) to compare the metabolic kinetics of ICP and its enantiomers in CYP and esterase; (4) to characterize the in vitro inhibition potencies of individual enantiomers of ICP and ICPO toward the AChE of Electrophorus electricus (EE-AChE) and recombinant human AChE (rH-AChE).
MATERIALS AND METHODS
Chemicals. Racemic isocarbophos (±ICP) and triazophos were purchased from Beijing Yaxier Science and Technology Ltd (Beijing, China) with purity >99%. Recemic isocarbophos oxon (±ICPO) was obtained from the Organization for the Prohibition of Chemical Weapon Laboratory (Beijing, China). Individual pure enantiomers [(+)enantiomer and (−)enantiomer] of ICP and ICPO (purity > 98%) were separated and prepared from (±)ICP and (±)ICPO following a modified procedure (Lin et al., 2008) . Bis(4-nitrophenyl) phosphoric acid (BNPP) was purchased from Beijing Bailingwei Science and Technology Ltd (Beijing, China). Ethylene glycol-bis-(2-aminoethylether)-N,N,N ,N -tetraacetic acid (EGTA), tetraisopropyl pyrophosphoramide (iso-OMPA), tranylcypromine, sulfaphenazole, quinidine, ketoconazole, bupropion, paclitaxel, acetylcholinesterases of recombinant human erythrocytes (rHAChE), E. electricus (EE-AChE, type V-S). Acetylthiocholine iodide (ATCh-I), and 5,5 -dithiobis-(2-nitrobenzoic acid) (DTNB) were obtained from Sigma-Aldrich (St Louis, MO). ␣-Naphthoflavone and ␤-NADPH were purchased from Roche Molecular Biochemicals (Basel, Switzerland). Recombinant human cytochromes P450 (CYP1A2, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4), recombinant human FMOs (FMO1, FMO3, and FMO5), and pooled human liver microsomes (HLMs) were provided by BD Gentest (Woburn, MA). All other reagents and solvents were of analytical grade and commercially available.
Quantification of ICP and ICPO.
The quantitative determination of ICP and ICPO was followed a published method (Wei et al., 2012 ). An Aglient 6430 triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an Agilent 1200 Infinity HPLC system and a ZORBAX SB-C18 column (50 mm × 2.1 mm, 1.8 m i.d.) was used in this study. The mobile phase consisted of 0.1% formic acid water solution (A) and methanol containing 0.1% formic acid (B). The gradient program applied was as follows: 0-2.5 min 40-80% B, 2.5-2.8 min 80% B, 2.81-4.0 min 40% B, followed by re-equilibration for 1.2 min. The column temperature was set at 25
• C and flow rate was 0.35 ml/min. For quantification, the instrument was operated in the ESI positive ion multiple reaction monitoring (MRM) mode with the following optimized MS/MS conditions: transfer capillary temperature of 350
• C; spray voltage of 3500 V. The selected transitions were m/z 231 → 111 for ICP, m/z 274 → 215 for ICPO, and m/z 314 → 215 for trizophos (IS). The linear quantitation ranges for ICP and ICPO were from 5 to 5000 ng/ml. The lower limit of detection of ICP and ICPO was 5 ng/ml.
Incubation of ICP and ICPO in recombinant FMOs and
HLMs. Preliminary experiments (data not shown) were performed to determine incubation conditions in HLMs that ensured linearity with respect to microsomal protein concentration and incubation time. As the result, a standard incubation mixture consisted of 0.4 mg/ml of human liver microsomes, 1M of substrate, 3.3mM of MgCl 2 , and 100mM of sodium phosphate buffer (pH 7.4). This experiment was performed in three parallel groups (ICP or ICPO alone and combination of ICP and ICPO). Substrates and microsomes were incubated at 37
• C to start the reaction. An aliquot (80 l) of the mixture was taken at 0, 5, 10, 15, 20, and 25 min and added to 160 l of stop solution (mixture of acetonitrile and methanol (1:1, vol/vol) containing 50 ng/ml trizophos, the IS). After centrifugation at 14,000 × g for 10 min, the supernatant was collected and analyzed by a HPLC-MS/MS method described above. Negative control incubations with inactive HLMs were conducted. All incubations were conducted in triplicate.
To investigate whether FMO is involved in the metabolism of ICP , the metabolic stability of ICP (1M) in HLM with and without heating treatment at 50
• C for 90 s was compared. Stability of ICP (1M) was further studied with recombinant FMO1, FMO3, or FMO5 (162 pmol/ml protein concentration, 0.2 mg protein/ml) in 50mM glycine buffer (pH 9.5), 1mM NADPH, and 3.3mM MgCl 2 for 30 min incubation.
Incubation of ICP with different kinds of esterase inhibitors in HLMs.
Preliminary experiments were performed to select the appropriate concentrations of different esterase inhibitors in HLMs to evaluate the contribution of CYP in the metabolism of ICP. The CYP activity was evaluated by a cocktail assay of six CYP isoforms established in our lab. The esterase inhibitors utilized including EGTA (1mM), BNPP (0.1-1mM), iso-PMPA (25-500M), EGTA (1mM) + iso-PMPA (50M), EGTA (1mM) + iso-PMPA (25M), or EGTA (1mM) + BNPP (1mM). The incubations with different inhibitors were preincubated at 37
• C for 5 min. Then 1M of ICP was added to initiate the reaction. All incubations were terminated after 30 min by the addition of 2× volume of stop solution. Control incubations with inactive HLMs or without inhibitor were conducted. All incubations were conducted in triplicate.
Incubation of ICP in HLMs with BNPP.
The preincubation mixtures consisted of 0.4 mg/ml of HLMs, 5M of ICP, 3.3mM of MgCl 2 , 1mM of BNPP, and 100mM of sodium phosphate buffer (pH 7.4). The reactions were initiated by the addition of NADPH (1mM) after incubation at 37
• C for 5 min. An aliquot of the mixture was taken at 0, 2, 5, 10, 15, and 25 min and added with stop solution. Negative control incubations with inactive HLMs or without BNPP were conducted. All incubations were conducted in triplicate.
Assay of ICP hydrolysis in the presence of ICPO in HLMs.
Varying concentrations of ICPO were added to ICP to assess the ability of ICPO to inhibit esterase metabolism. The alternations of ICP hydrolysis reaction rate in HLMs were firstly conducted by coincubation with different concentrations of ICPO (0, 0.01, 0.05, and 0.1M) and ICP (1M) at 37
• C. An aliquot of the mixture was taken at 0, 2, 5, 10, 15, and 25 min and added with stop solution. To further determine the IC 50 of ICPO toward ICP hydrolysis by esterase, series of ICPO (0, 0.01, 0.02, 0.05, 0.15, 0.5, 1.5, and 5M) was coincubated with ICP (50M). The preincubation mixtures consisted of HLMs, 3.3mM of MgCl 2 , and 100mM of sodium phosphate buffer (pH 7.4). The reactions were initiated by the addition the NADPH after preincubation of ICP and ICPO in HLMs at 37
• C for 5 min. All incubations were terminated at 10 min by the addition of stop solution. All incubations were conducted in triplicate. The amount of ICP remaining at each ICPO concentration relative to the control (percentage of remaining activity, log transformed) was plotted against the concentration of the inhibitor, ICPO. The IC 50 values were calculated using nonlinear regression analysis using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA).
Identification of CYP involved in the production of ICP oxidative desulfurization metabolite (ICPO) in HLMs using chemical inhibitors.
The assays were performed using HLMs in the presence of 1mM of BNPP to inhibit the carboxylesterase activity. The preincubation mixtures consisted of 0.4 mg/ml of HLMs, 1M of ICP, 3.3mM of MgCl 2 , and 100mM of sodium phosphate buffer (pH 7.4) in the absence (control) and presence of selective CYP chemical inhibitors. The reactions were started by the addition of NADPH and incubation lasted for 30 min. The inhibitors were ␣-naphthol (10M) for CYP1A2, sulfaphenazole (40M) for CYP2C9, tranylcypromine (400M) for CYP2C19, quinidine (10M) for CYP2D6, and ketoconazole (1M) for CYP3A4. At the end of incubation, stop solution was added. All incubations were conducted in triplicate.
Metabolism of ICP to ICPO by cDNA-expressed CYP isoforms. The incubation mixture contained Supersomes (25 pmol protein/ml), MgCl 2 (3.3mM), NADPH (1mM), and ICP (1M) in a final volume of 200 l of potassium phosphate buffer (100mM, pH 7.4). Each of the recombinant CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 were tested in separate incubations. Preincubations were performed at 37
• C for 5 min, and the reaction was initiated by the addition of NADPH. After incubation for 60 min, the reaction was terminated by adding stop solution. Negative control incubations with control rCYP (egg white protein) were conducted. All incubations were conducted in triplicate.
The oxidation kinetics of formation of ICPO and its enantiomers in HLMs. ICP and its enantiomers [(+)ICP, or (−)ICP]
at the concentration ranging 0.1 and 200M were incubated with human liver microsomes at 37
• C. Reactions were initiated by the addition of NADPH. At 0 (controls) or 30 min, stop solution was added. A chiral LC-MS/MS method was used to determine the amount of ICPO and its enantiomers. All incubations were conducted in triplicate.
The hydrolysis kinetics of ICP and its enantiomers in HLMs. ICP and its enantiomers [(+)ICP, or (−)ICP] at the concentration range between 0.1 and 200M were incubated with HLMs in the absence of NADPH and/or BNPP in a 37
• C water bath. The reactions were terminated after incubation for 0 (controls) or 5.5 min by adding stop solution. A chiral LC-MS/MS method was used to determine the remaining amount of ICP and its enantiomers. All incubations were conducted in triplicate.
Assay of AChE inhibition by ICP and ICPO.
The in vitro inhibition of AChE activities was evaluated using two enzymes, rH-AChE and EE-AChE. The substrate hydrolysis rate was limited within 0.05-0.10 A/min by optimizing the enzyme concentration through a preliminary study. Briefly, test solutions (20 l) at various concentrations of (±)ICP, (±)ICPO, (+)ICPO, and (−)ICPO that could inhibit enzyme activity by 10-90% were added into a 96-well plate, followed by addition of 80 l of AChE solution. Then 150 l of ATCh (0.5mM) and DTNB (0.28mM) solutions were added and the mixture was incubated at 37
• C for different time to measure the remaining enzyme activity [E r ] by reading the absorption at 412 nm for 3 min at intervals of 30 s. Control samples were prepared by using 20 l of phosphate buffer (pH 8.0), instead of test solution, to measure the initial enzyme activity [E 0 ]. All experiments were performed in four replicate.
Data analysis. The velocity data of product formation from substrate were fit with Michaelis-Menten kinetics. The EadieHofstee plots were also employed to estimate whether multiple enzymes were involved in the reaction. The enzyme kinetic parameters (K m,app and V max ) were determined from a nonlinear least-squares regression analysis (Sigma Plot, SPSS Inc., Chicago, IL). The CL int is defined as the ratio of V max /K m,app . The AChE inhibition rate constants including k p , K i , and k app were calculated based on the inhibition mechanism described by Kitz (Kitz and Wilson, 1962) . Under a given inhibitor concentration [I], the apparent phosphorylation rate constant, k app , can be calculated using the Equation 1:
Equation 1 The k app can then be converted to the following linear form: By plotting the reciprocal of k app versus the reciprocal of [I], k p and K i can be obtained from the slope and intercept of the linear regression line. The dissociation constant, K d , is defined as k p /K i . As an indicator of inhibitor sensitivity to an enzyme, IC 50 (the concentration of inhibitor producing half-inhibition of enzyme activity) can be calculated using the Equation 3:
RESULTS

Involvement of FMO and Non-NADPH Metabolism of ICP and ICPO
When ICP is incubated with recombinant FMO1, FMO3, and FMO5, no appreciable loss of parent compound was observed after 30 min incubation ( Fig. 2A) . There was also no difference in human liver microsomal clearance after the FMOs were inactivated by heating treatment (data not shown). The elimination curve of ICP and ICPO in HLMs in the absence of NADPH was presented in Figure 2B suggesting that the non-CYP metabolism is significant for ICP but low for ICPO. The depletion of ICP is linear within 0-25 min.
Identification of Esterase Involved in Hydrolysis of ICP in HLMs
The effects of different esterase inhibitors on the stability of ICP in HLMs in the absence of NADPH were showed in Fig-44 ZHUANG ET AL. 
FIG. 3.
Influence of different esterase inhibitors on stability of ICP and ICPO in HLM in the absence of NADPH. Incubation with inactive HLM was set as negative control group with 100% turnover activity. Incubation without inhibitors in HLM was set as positive control. Significant differences from positive control were assessed by t-test. *p < 0.05, **p < 0.01 (n = 3, each bar represents the mean ± SD). ure 3. Compared with the inactivated HLMs, the inhibition of non-CYP metabolism of ICP by BNPP, a specific inhibitor of carboxylesterase, was profound. Furthermore, the inhibition by BNPP was concentration dependent, and carboxylesterase activity was close to be completely blocked (∼97%) at 1mM. The dual inhibitor of choline esterase and carboxylesterase iso-PMPA showed an inhibition of 67% at 500M. On the other hand, minimal inhibition was observed when EGTA, a calcium chelator or paraoxonase (PON) inhibitor was used. Hence, it seemed that carboxylesterase is the main enzyme responsible for the hydrolysis of ICP in HLMs.
The Effects of BNPP on the Elimination of ICP and Formation of ICPO in HLMs
When ICP was incubated with HLMs in the presence of BNPP, the elimination of ICP was slowed down dramatically (Fig. 4A) . Meanwhile, ICPO formation increased timedependently during the first 25 min. The concentration of ICPO was ∼3-fold greater than the incubation group supplemented with NADPH but not BNPP (Fig. 4B) . Elimination half-life of ICP under different incubation conditions were summarized in Table 1 . The depletion of ICP prolonged from 11.9 ± 1.24 to 90.0 ± 1.17 min in the presence of BNPP.
The Inhibitory Effect of ICPO on ICP Hydrolysis
When ICP was incubated with ICPO in HLMs, the decrease of elimination rate of ICP was ICPO concentration-dependent (Fig. 5A) . The inhibition curve of ICPO in HLMs is shown in Figure 5B . IC 50 value of 0.133 ± 0.018M suggested that ICPO is a potent inhibitor toward the esterase-mediated hydrolysis of ICP.
Identification of CYP450 Isoforms Responsible for the Desulfurization of ICP in HLMs
The formation of ICPO was evaluated in seven cDNAexpressed human P450 isoforms. CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 all catalyzed ICP oxidative desulfurization, with the highest activities observed in CYP1A2 and CYP3A4 incubations (Table 2) . No contribution was detected by CYP2B6 and CYP2E1. Chemical inhibitors were used to confirm these findings in HLMs. High inhibition of ICPO formation (67%) was achieved with ketoconazole (CYP3A4-selective). Other CYP inhibitors, such as quinidine (CYP2D6-selective), sulfaphenazole (CYP2C9-selective), ␣-naphthoflavone (CYP1A2-selective), and tranylcypromine (CYP2C19-selective) all inhibited the formation of ICPO at certain extent. Overall, the results of this experiment demonstrated that CYP3A4 played a major role in the ICP desulfurization reaction.
CYP-Mediated Enzyme Kinetics of ICP and its Enantiomers in
HLMs CYP-mediated metabolism of ICP and its enantiomers was mainly through oxidation desulfurization. No optical conversion was observed, i.e., two ICP enantiomers only generated Note. The incubation mixture contained Supersomes (25 pmol protein/ml), MgCl 2 (3.3mM), NADPH (1mM), and ICP (1M) in a final volume of 200 l of potassium phosphate buffer (100mM, pH 7.4). their respective optical metabolites. Hence, enzyme kinetics of ICP and its enantiomers in HLMs were evaluated using the formation rates of ICPO metabolites, instead of the optical metabolites, and the results are presented in Figure 5 . The estimated kinetic constants are listed in Table 3 . The values of CYPmediated CL int of (±)ICP, (+)ICP, and (−)ICP in HLMs were 8.99 ± 2.13, 8.25 ± 0.61, and 7.28 ± 2.46 ml/min/mg, respectively, that are significantly lower than the corresponding clearances of esterase in HLMs (184 ± 8.14, 260 ± 5.05, and 296 ± 53.7 ml/min/mg, Table 4 ). These results suggested that the oxidation desulfurization reaction by human liver cytochrome P450 played a minor role in the overall clearance of ICP. Furthermore, the apparent K m and V max for (±)ICP and its two enantiomers are similar (Table 3) , which suggests that the stereoselectivity of ICP metabolism by CYP is negligible.
Compound-Dependent and Enantioselectivity in AChE Inhibition
The inhibition of EE-AChE or rH-AchE by (±)ICP, (±)ICPO, (+)ICPO, and (−)ICPO are summarized in Table 5 . A significant difference in IC 50 was observed between (±)ICP and (±)ICPO, as well as (+)ICPO and (−)ICPO for both enzymes EE-AchE and rH-AchE. For example, the inhibition potency of (±)ICPO to EE-AchE and rH-AchE were nearly 3000-to 6000-fold greater than (±)ICP, whereas the inhibition potency of (+)ICPO to EE-AchE or rH-AchE were 90-to 200-fold greater than (−)ICPO.
DISCUSSION
A unique feature of metabolism of a chiral drug is the possibility of undergoing metabolic inversion of configuration at the asymmetric center (Susan et al., 1990) . In this study, the chiral inversion of ICP in HLMs was firstly investigated for the oxidative desulfuration reaction. The results indicated that neither racemization nor metabolic inversion occurred during the incubation (data not shown), i.e., each enantiomer parent compound transformed to their corresponding oxidative desulfuration metabolite (Fig. 6) .
The activation (to the oxon) and detoxification of major OP compounds often involve the P450, PON1 (aryldialkylphosphatase), and B-esterases, such as carboxylesterase (Sogorb and Vilanova, 2011) . The liver expresses large amount of P450, PON1, and B-esterases, therefore the hepatic metabolism of OP plays an important role in its toxicity (Sultatos et al., 1984; Sultatos and Minor, 1986) . In the present work, we investigated the role of P450 and esterase in the activation and detoxification of ICP in HLMs. The rates of elimination and intrinsic hepatic clearance of ICP was assessed in the presence and absence of NADPH or esterase inhibitor BNPP. In the absence of NADPH and BNPP, the major enzyme involved in the metabolism of ICP is esterase, whereas in the presence of NADPH and BNPP, the working enzyme is mainly CYP to metabolize ICP to ICPO. The metabolic stability results indicated that the relative rates of hydrolysis and oxidation of ICP in HLMs had great difference with t 1/2 of 5.2 min in esterasemediated hydrolysis compared with 90.0 min in CYP-mediated metabolism. The enzyme kinetic studies of ICP and its enantiomers further showed that the K m,app values were at the same level, but significant higher V max (∼30-50 times) was observed in esterase reaction suggesting the esterase-mediated hydrolysis is the predominant elimination and detoxification pathway of ICP in HLMs. However, inhibition of carboxylesterase would dramatically increase the toxicity of ICP. Thus, coadministration of carboxylesterase inhibitors should be avoided by the operators who handle ICP. Besides CYP-mediated oxidative metabolism of organophosphate, FMOs has been reported responsible for the sulfoxidation of several heteroatoms pesticides (Usmani et al., 2004) . In adult humans, FMO3 and FMO5 are the major hepatic isoforms, whereas FMO1 primarily presents in kidney and intestines. In our study, ICP was found metabolically stable in recombinant FMO1, FMO3, or FMO5.
It was interesting to observe in this study that the clearance of ICP is even slower in HLMs with NADPH (esterase + CYP) compared with the incubation without NADPH, in which the clearance is mediated by esterase only (Fig. 4A and Table 1). Although the exact clearance mechanism is unknown, several possibilities could have contributed to this observation. It has been reported that during the CYP-mediated OP metabolism converting the thione (P = S) to the corresponding oxon (P = O), reactive and/or inhibitory intermediates could form and inhibit a number of enzymes including AChE, carboxylesterase (Casida and Quistad, 2004) , and even the CYPs themselves (Tang et al., 2002) . The released sulfur ion during the CYP-mediated desulfuration reaction can suppress CYP activity through binding to the heme group (Neal and Halpert, 1982) . Thus, the NADPH-mediated reaction may have an autoinhibition effect on NADPH dependent ICP metabolism. On the other hand, ICPO was found to inhibit ICP hydrolysis in this study with IC 50 of 0.133 ± 0.018M. This finding also suggests the possibility of metabolite-mediated inhibition of the parent hydrolysis. Nevertheless, the inhibition mechanism of ICPO toward carboxylesterase warrant further investigation.
In addition, the data in Figure 4B showed that more ICPO was generated in the incubations of ICP + BNPP + NADPH compared with ICP + NADPH. These findings may suggest that the increased ICP concentration due to a slower carboxylesterase hydrolysis in the presence of BNPP might have provided a higher precursor concentration for ICPO formation. As described early, ICPO is a CYP-mediated metabolite of ICP. Thus, the metabolism pathways could have shifted in the presence of BNPP.
Despite the fact that the oxidative metabolism of ICP is considerably slower than esterase hydrolysis, the increased toxicity of oxon formed via the oxidative pathway deserves more attentions. In HLMs, multiple CYPs were involved in the oxidative desulfurization reaction of ICP. Among the CYP isoforms, CYP3A4 and CYP1A2 play significant roles in the bioactivation of ICP. This is consistent with the previous finding showing that individual CYP1A2 activity could be used as a surrogate biomarker for OP-induced toxicity in humans (Buratti et al., 2007) . CYP1A2 can be induced by common habits such as smoking or consumption of caffeine-containing beverages and well-done meat (Zhuang et al., 2013) . On the other hand, CYP3A4 is the most abundant CYP isoform associated with drug metabolism in human liver (Shimada et al., 1994) , which can be induced several folds by a number of market drugs (Roy et al., 1999) . Individuals with high levels of CYP1A2 and CYP3A4 activities would be expected to produce higher level of oxon metabolites when exposure to OPs. Consequently, susceptible to adverse effects induced by this class of pesticides. The inhibition of CYP3A4 might be proposed as a possible complementary therapy in treating severe acute poisoning of ICP or other OPs induced poisoning (Buratti et al., 2007) .
Although the enantioselectivity in CYP-mediated and in esterase-mediated enzyme kinetics of ICP is absent, the enantioselectivity in AChE inhibition by ICPO is obvious. Examination of the rate constants in Table 3 offers an insight of the different inhibition potencies among these racemate and enantiomers. Taking the EE-AChE inhibition as an example, the k d value for (−)ICPO was 54.4 times higher than that for the (+)enantiomer. The (+)ICPO was thus preferentially bound to EE-AChE as compared to its (−)enantiomer. On the other hand, the k p values remained relatively constant for the racemate and enantiomers, indicating that the phosphorylation in this case was little enantioselective. Similar observation could be derived for rH-AChE. It can then be concluded that the enantioselective inhibition of ICPO toward rH-AChE and EE-AChE arose primarily from the preferential binding of the (+)enantiomer in relative to the (−)enantiomer.
In summary, the mechanism of ICP metabolism presented in the current study highlights that human liver microsomes has a greater capacity for detoxification of ICP and a relatively lower capacity of activating ICP to its active metabolites that are potent acetylcholinesterase inhibitor. For the first time, we reveal that the absence of enantioselectivity in CYP-mediated and esterase-mediated enzyme kinetics for ICP. In addition, the inhibition of ICPO to rH-AChE and EE-AChE is enantioselective. The significant enantioselectivity of ICPO toward AChE inhibition suggests that enantiomers need to be assessed individually for their environmental safety. It is also important to look into the overall toxicity of all the metabolites or enantiomers when we evaluate the risk and benefit of OP compounds, such as ICP. 
